medigraphic.com
ISSN 1561-2937 (Impreso)

2021, Número 3

<< Anterior Siguiente >>

Rev Cubana Cardiol Cir Cardiovasc 2021; 27 (3)


Hierro y falla cardíaca, dos comorbilidades para prestar atención

Lobo SYF

Idioma: Español
Referencias bibliográficas: 49
Paginas: 1-9
Archivo PDF: 364.64 Kb.


RESUMEN

La falla cardíaca es un síndrome complejo causado por alteraciones estructurales y/o del funcionamiento cardíaco que llevan a manifestaciones sintomáticas como disnea y cansancio; afecta a aproximadamente 26 millones de personas en el mundo. El hierro es un mineral esencial para el correcto funcionamiento de los músculos que obtienen su energía por medio de procesos como la fosforilación oxidativa y el ciclo de Krebs los cuales se llevan a cabo en la mitocondria. El miocardio cuenta con un gran número de estas organelas, por tal motivo, alteraciones en el balance de este mineral pueden generar fallos sistemáticos que lleven a disfunción muscular. Aproximadamente la mitad de los pacientes con falla cardíaca desarrolla déficit de hierro, una comorbilidad que puede aparecer con o sin anemia y que por sí sola empeora los signos y síntomas de la enfermedad. Para su diagnóstico se tiene en cuenta los niveles séricos de ferritina y la saturación de transferrina. Las últimas guías de manejo indican que el tratamiento debe ser hierro en su forma intravenosa puesto que se ha demostrado que tiene grandes beneficios en la reversibilidad de la remodelación cardíaca, en la clasificación funcional de esta y en la percepción de calidad de vida de los pacientes. La presente revisión se hizo con el fin de recolectar la información disponible en la literatura y determinar qué alternativas de tratamiento derivan en una mejor calidad de vida.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Lima LF, Barbosa F Júnior, Simões MV, Navarro AM. Heart failure, micronutrient profile, and its connection with thyroid dysfunction and nutritional status. Clin Nutr. 2019; 38(2):800-05. doi: 10.1016/j.clnu.2018.02.030

  2. Jameson JL, editor. Harrison’s principles of internal medicine. 20. Ed. New York: McGraw-Hill Education, 2018; volumen 2

  3. Jacob C, Altevers J, Barck I, Hardt T, Braun S, Greiner W. Retrospective analysis into differences in heart failure patients with and without iron deficiency or anaemia. ESC HEART FAILURE. 2019; 6:840-55. doi: 10.1002/ehf2.12485

  4. Rognoni C, Gerzeli S. Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost-effectiveness and budget impact. J Comp Eff Res. 2019;8(13):1099-110. doi: 10.2217/cer-2019-0074

  5. Dereli S, Bayramoğlu A, Özer N, Cerşit S, Kaya A, Özbilen M. Evaluation of left atrial volume and function by real time three dimensional echocardiography in anemic patients without overt heart disease before and after anemia correction. Int J Cardiovasc Imaging. 2019;35(9):1619-626. doi: 10.1007/s10554-019-01609-6

  6. Yardany R, Méndez EY, Caicedo DS, Fernández KE, Reyes SL, Manrique MD, et al. Eficacia y seguridad del uso de hierro en el tratamiento de la falla cardíaca: revisión sistemática. Rev Colomb Cardiol. 2019; 26(4):185-97. Doi: 10.1016/j.rccar.2018.10.013

  7. De Las Nieves MA. Should oral iron be dismissed in patients with heart failure? BMJ Evid Based Med. 2019. [Epub ahead of print] doi: 10.1136/bmjebm-2019-111198.

  8. Mistry R, Hosoya H, Kohut A, Ford P. Iron deficiency in heart failure, an underdiagnosed and undertreated condition during hospitalization. Ann Hematol. 2019; 98(10): 2293-297. doi: 10.1007/s00277-019-03777-w

  9. Arias-Barrera C, Palacios-Ariza MA, Pradilla I, Alvarez-Moreno C. A cohort study of two intravenous treatments for iron deficiency in patients with heart failure. Acta Cardiol. 2019:1-8. doi: 10.1080/00015385.2019.1639270

  10. Sánchez EM, Vera CY, Navas CM, Ortiz SD, Rodríguez C, Vargas DM, et al. Validación para Colombia del cuestionario para la “medición de la capacidad funcional en pacientes con falla cardíaca”. Rev Colomb Cardiol. 2018;25(6):356-65. doi: 10.1016/j.rccar.2018.04.004

  11. Sutil-Vega M, Rizzo M, Martínez-Rubio A. Anemia and iron deficiency in heart failure: a review of echocardiographic features. Echocardiography. 2019;36(3):585-94. doi: 10.1111/echo.14271

  12. Arora H, Sawhney JPS, Mehta A, Mohanty A. Anemia profile in patients with congestive heart failure a hospital based observational study. Indian Heart J. 2018;70 (Suppl 3):S101-S104. doi: 10.1016/j.ihj.2018.06.017

  13. Pfister O. Anemia and Iron Deficiency in Heart Failure. In: Feldman DS, Mohacsi P, editores. Heart Failure [Internet]. Cham: Springer; 2019 [consultado el 22 de abril de 2020]. p. 171-8. (Cardiovascular medicine). Disponible en: http://link.springer.com/10.1007/978-3-319-98184-0_12

  14. Hubert M, Gaudriot B, Biedermann S, Gouezec H, Sylvestre E, Bouzille G, et al. Impact of Preoperative Iron Deficiency on Blood Transfusion in Elective Cardiac Surgery. J Cardiothorac Vasc Anesth. 2019;33(8):2141-150. doi: 10.1053/j.jvca.2019.02.006

  15. Zusman O, Itzhaki Ben Zadok O, Gafter-Gvili A. Management of Iron Deficiency in Heart Failure. Acta Haematol. 2019;142(1):51-56. doi: 10.1159/000496822

  16. Nikolaou M, Chrysohoou C, Georgilas TA, Giamouzis G, Giannakoulas G, Karavidas A, et al. Management of iron deficiency in chronic heart failure: Practical considerations for clinical use and future directions. Eur J Intern Med. 2019;65:17-25. doi: 10.1016/j.ejim.2019.05.011

  17. Sirbu O, Sorodoc V, Jaba IM, Floria M, Stoica A, Profire L, et al. The Influence of Cardiovascular Medications on Iron Metabolism in Patients with Heart Failure. Medicina (Kaunas). 2019;55(7). pii: E329. doi: 10.3390/medicina55070329

  18. Lakhal-Littleton S. Mechanisms of cardiac iron homeostasis and their importance to heart function. Free Radic Biol Med. 2019; 133:234-37. doi: 10.1016/j.freeradbiomed.2018.08.010

  19. Magrì D, De Martino F, Moscucci F, Agostoni P, Sciomer S. Anemia and Iron Deficiency in Heart Failure: Clinical and Prognostic Role. Heart Fail Clin. 2019;15(3):359-69. doi: 10.1016/j.hfc.2019.02.005

  20. Zhang H, Zhabyeyev P, Wang S, Oudit GY. Role of iron metabolism in heart failure: From iron deficiency to iron overload. Biochim Biophys Acta Mol Basis Dis. 2019 Jul 1;1865(7):1925-937. doi: 10.1016/j.bbadis.2018.08.030

  21. Lakhal-Littleton S. Iron Deficiency as a Therapeutic Target in Cardiovascular Disease. Pharmaceuticals (Basel). 2019;12(3). pii: E125. doi:10.3390/ph12030125

  22. Hoes MF, Grote Beverborg N, Kijlstra JD, Kuipers J, Swinkels DW, Giepmans BNG, et al. Iron deficiency impairs contractility of human cardiomyocytes through decreased mitocondrial function. Eur J Heart Fail. 2018;20(5):910-19. doi: 10.1002/ejhf.1154

  23. Adlbrecht C. Intravenous iron therapy for patients with heart failure: expanding body of evidence. ESC Heart Fail. 2019;6(4):581-83. doi:10.1002/ehf2.12490

  24. Lupu M, Tudor DV, Filip GA. Influence of mitochondrial and systemic iron levels in heart failure pathology. Heart Fail Rev. 2019;24(5):647-59. doi: 10.1007/s10741-019-09788-z

  25. Martens P, Dupont M, Dauw J, Somers F, Herbots L, Timmermans P, et al. Rationale and design of the IRON-CRT trial: effect of intravenous ferric carboxymaltose on reverse remodelling following cardiac resynchronization therapy. ESC Heart Fail. 2019. doi: 10.1002/ehf2.12503

  26. Kumar V, A AK, Sanawar R, Jaleel A, Santhosh Kumar TR, Kartha CC. Chronic Pressure Overload Results in Deficiency of Mitochondrial Membrane Transporter ABCB7 Which Contributes to Iron Overload, Mitochondrial Dysfunction, Metabolic Shift and Worsens Cardiac Function. Sci Rep. 2019;9(1):13170. doi:10.1038/s41598-019-49666-0

  27. Anand IS, Gupta P. Anemia and Iron Deficiency in Heart Failure: Current Concepts and Emerging Therapies. Circulation. 2018;138(1):80-98. doi:10.1161/CIRCULATIONAHA.118.030099

  28. Vela D. Keeping heart homeostasis in check through the balance of iron metabolism. Acta Physiol (Oxf). 2019:e13324. doi: 10.1111/apha.13324.

  29. Bekfani T, Pellicori P, Morris D, Ebner N, Valentova M, Sandek A, et al. Iron deficiency in patients with heart failure with preserved ejection fraction and its association with reduced exercise capacity, muscle strength and quality of life. Clin Res Cardiol. 2019;108(2):203-11. doi: 10.1007/s00392-018-1344-x

  30. Bakogiannis C, Briasoulis A, Mouselimis D, Tsarouchas A, Papageorgiou N, Papadopoulos C, et al. Iron deficiency as therapeutic target in heart failure: a translational approach. Heart Fail Rev. 2019. doi:10.1007/s10741-019-09815-z

  31. González-Costello J, Comín-Colet J, Lupón J, Enjuanes C, de Antonio M, Fuentes L, et al. Importance of iron deficiency in patients with chronic heart failure as a predictor of mortality and hospitalizations: insights from an observational cohort study. BMC Cardiovasc Disord. 2018;18(1):206. doi:10.1186/s12872-018-0942-x

  32. Wienbergen H, Pfister O, Hochadel M, Fach A, Backhaus T, Bruder O, et al. Long-term effects of iron deficiency in patients with heart failure with or without anemia: the RAID-HF follow-up study. Clin Res Cardiol. 2019;108(1):93-100. doi:10.1007/s00392-018-1327-y

  33. Paterek A, Kępska M, Sochanowicz B, Chajduk E, Kołodziejczyk J, Polkowska-Motrenko H, et al. Beneficial effects of intravenous iron therapy in a rat model of heart failure with preserved systemic iron status but depleted intracellular cardiac stores. Sci Rep. 2018;8(1):15758. doi: 10.1038/s41598-018-33277-2

  34. Ambrosy AP, Gurwitz JH, Tabada GH, Artz A, Schrier S, Rao SV, et al: RBC HEART Investigators. Incident anaemia in older adults with heart failure: rate, aetiology, and association with outcomes. Eur Heart J Qual Care Clin Outcomes. 2019;5(4):361-69. doi: 10.1093/ehjqcco/qcz010

  35. Karim R, Cader FA, Haq MM, Sultana N, Hussain M, Khandoker F. Prevalence of anaemia among patientes with heart failura in a tertiary care cardiac centre of Bangladesh. J Invasive Clin Cardiol. 2019; 1(1): 9-14. doi: 10.5830/CVJA-2015-021

  36. Rineau E, Gaillard T, Gueguen N, Procaccio V, Henrion D, Prunier F, et al. Iron deficiency without anemia is responsible for decreased left ventricular function and reduced mitochondrial complex I activity in a mouse model. Int J Cardiol. 2018; 266:206-12. doi: 10.1016/j.ijcard.2018.02.021

  37. Beale AL, Warren JL, Roberts N, Meyer P, Townsend NP, Kaye D. Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Open Heart. 2019;6(1):e001012. doi:10.1136/openhrt-2019-001012

  38. Bourguignon S, Faller M, Champs FO, Moutier H, Levesque K, Caranhac G, et al. Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France. ESC Heart Fail. 2019;6(3):559-69. doi: 10.1002/ehf2.12432

  39. Kobak KA, Radwańska M, Dzięgała M, Kasztura M, Josiak K, Banasiak W, et al.Structural and functional abnormalities in iron-depleted heart. Heart Fail Rev. 2019;24(2):269-77. doi:10.1007/s10741-018-9738-4

  40. Schwartz AJ, Converso-Baran K, Michele DE, Shah YM. A genetic mouse model of severe iron deficiency anemia reveals tissue-specific transcriptional stress responses and cardiac remodeling. J Biol Chem. 2019;294(41):14991-15002. doi: 10.1074/jbc.RA119.009578

  41. Malfatto G, Frisinghelli A, Ambrosetti M, La Rovere MT, Motta I, Passaretti B, et al. Iron deficiency from the standpoint of cardiac rehabilitation: novel therapeutic opportunities. Monaldi Archives for Chest Disease. 2019; 89(3). doi: 10.4081/monaldi.2019.1118

  42. Meier R, Keizer E, Rosemann T, Markun S. Indications and associated factors for prescribing intravenous iron supplementation in Swiss general practice: a retrospective observational study. Swiss Med Wkly. 2019;149:w20127. doi: 10.4414/smw.2019.20127

  43. Zdravkovic SC, Nagorni SP, Cojbasic I, Mitic V, Cvetkovic P, Nagorni I, et al. Effects of 6-months of oral ferrous and ferric supplement therapy in patients who were hospitalized for decompensated chronic heart failure. J Int Med Res. 2019;47(7):3179-189. doi:10.1177/0300060519847352

  44. Spahn DR, Schoenrath F, Spahn GH, Seifert B, Stein P, Theusinger OM, et al. Effect of ultra-short-term treatment of patients with iron deficiency or anaemia undergoing cardiac surgery: a prospective randomised trial. Lancet. 2019;393(10187):2201-212. doi:10.1016/S0140-6736(18)32555-8

  45. Bruno ML, Rocha MD, Gonzalo JL, Cunha MD, Menezes LF. The burden of iron deficiency in heart failure. JACC. 2018; 71 (7). 782-93. doi: 10.1016/j.jacc.2017.12.027.

  46. Martin-Malo A, Borchard G, Flühmann B, Mori C, Silverberg D, Jankowska EA. Differences between intravenous iron products: focus on treatment of iron deficiency in chronic heart failure patients. ESC Heart Fail. 2019;6(2):241-53. doi: 10.1002/ehf2.12400

  47. Martens P, Minten L, Dupont M, Mullens W. The importance of dose optimisation in the treatment of iron deficiency in heart failure. Acta Cardiol. 2019: Jun:1-5. doi: 10.1080/00015385.2019.1625554.

  48. Zhou X, Xu W, Xu Y, Qian Z. Iron Supplementation Improves Cardiovascular Outcomes in Patients with Heart Failure. Am J Med. 2019;132(8):955-63. doi: 10.1016/j.amjmed.2019.02.018

  49. Mini P, Marc B, Fabien S, Chuzeville M. Prevalence ofi ron deficiency in patients aged 75 years or older with heart failure. J Geriatr Cardiol. 2018;15:682-86. doi: 10.11909/j.issn.1671-5411.2018.11.005




2020     |     www.medigraphic.com